Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination

Bochnia-Bueno, Lucas; Almeida, Sérgio Monteiro de; Raboni, Sônia Mara; Adamóski, Douglas; Amadeu, Ludmilla Louise Moreira; Carstensen, Suzana; Nogueira, Meri Bordignon

doi:10.1016/j.diagmicrobio.2021.115597

Cited by 17 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We report that all Comirnaty recipients had no detectable IgG-N as expected. Meanwhile, no CoronaVac recipient had detectable IgG-N after the first dose, the positivity increased to 58.4% three weeks after the second dose (week six), which is similar to the findings of others in Thailand and Southern Brazil, whereby 1% 41 and 57–62.8% 41 , 42 were IgG-N positive after the first and second doses, respectively. Interestingly, Muena et al, reported that CoronaVac failed to boost the IgG-N titer in previously infected individuals, concluding that CoronaVac is a poor N immunogen 29 .…”

Section: Discussionsupporting

confidence: 88%

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia

Tan

Noni

Melina

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Several vaccines have been fast-tracked through clinical trials to mitigate the progression of the SARS‑CoV‑2 pandemic. We analyzed sequential blood samples from 314 recipients of Comirnaty and CoronaVac in East Malaysia for the spike-binding IgG (IgG-S), nucleocapsid-binding IgG (IgG-N), spike-binding IgM (IgM-S) and serum vitamin D (VitD). A subset of samples was analyzed for the neutralizing antibodies (Ig-RBD). Results showed that IgG-S due to Comirnaty was significantly higher than CoronaVac. IgM-S was detected in 80.0% Comirnaty and 69.5% CoronaVac recipients, while IgG-N was detected in 58.1% CoronaVac but not in Comirnaty recipients. All IgG-S-positive vaccines possessed detectable Ig-RBD after the second dose but with a weak to moderate correlation. The serum VitD levels did not influence the antibody magnitude in both vaccines. In essence, SARS-CoV-2 vaccination is an IgG-S-dominant event, Comirnaty was more effective than CoronaVac in mounting IgG-S and Ig-RBD responses, independent of the patient’s VitD level.

show abstract

Section: Discussionsupporting

confidence: 88%

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia

Tan

Noni

Melina

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Here we applied our assay to sera from individuals with or without a previous SARS-CoV-2 infection, who were vaccinated with CoronaVac (a purified inactivated SARS-CoV-2 vaccine) 19 , or ChAdOx1 nCoV-19 (the adenovirus-vectored vaccine encoding SARS-CoV-2 spike protein) 20 . Due to the contact with all the viral proteins in vaccination with CoronaVac, a serological response to protein N is expected and detected in other studies 19 , 48 , although we did not observe this result in the tested samples. On the other hand, the response against N-NTD can be useful to identify pre-vaccination infections.…”

Section: Discussioncontrasting

confidence: 79%

On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination

Fernandes-Siqueira

Ferreira

Sousa

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The Covid-19 pandemic, caused by SARS-CoV-2, has resulted in over 6 million reported deaths worldwide being one of the biggest challenges the world faces today. Here we present optimizations of all steps of an enzyme-linked immunosorbent assay (ELISA)-based test to detect IgG, IgA and IgM against the trimeric spike (S) protein, receptor binding domain (RBD), and N terminal domain of the nucleocapsid (N-NTD) protein of SARS-CoV-2. We discuss how to determine specific thresholds for antibody positivity and its limitations according to the antigen used. We applied the assay to a cohort of 126 individuals from Rio de Janeiro, Brazil, consisting of 23 PCR-positive individuals and 103 individuals without a confirmed diagnosis for SARS-CoV-2 infection. To illustrate the differences in serological responses to vaccinal immunization, we applied the test in 18 individuals from our cohort before and after receiving ChAdOx-1 nCoV-19 or CoronaVac vaccines. Taken together, our results show that the test can be customized at different stages depending on its application, enabling the user to analyze different cohorts, saving time, reagents, or samples. It is also a valuable tool for elucidating the immunological consequences of new viral strains and monitoring vaccination coverage and duration of response to different immunization regimens.

show abstract

“…or ChAdOx1 nCoV-19 (the adenovirus-vectored vaccine encoding SARS-CoV-2 spike protein) [24]. Due to the contact with all the viral proteins in vaccination with CoronaVac, a serological response to protein N is expected and detected in other studies [23,51], although we did not observe this result in the tested samples. On the other hand, the response against N-NTD can be useful to identify pre-vaccination infections.…”

Section: Discussioncontrasting

confidence: 56%

On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination

Fernandes-Siqueira

Abdalla

Sousa

et al. 2022

Preprint

View full text Add to dashboard Cite

The Covid-19 pandemic, caused by SARS-CoV-2, resulted in more than 5 million deaths being one of the biggest challenges the world faces today. Here we present optimizations to all steps of an enzyme-linked immunosorbent assay (ELISA)-based test to detect IgG, IgA and IgM against the trimeric spike (S) protein, receptor binding domain (RBD), and N terminal domain of the nucleocapsid (N-NTD) protein of SARS-CoV-2. We discuss how to determine the specific thresholds for antibody positivity and its limitations according to the antigen used. We applied the assay in a cohort of 126 individuals from Rio de Janeiro, Brazil, consisting of 23 PCR-positive individuals; and 103 individuals without confirmed diagnosis for SARS-CoV-2 infection. To illustrate the differences in serological responses to vaccinal immunization, we applied the test in 18 individuals of our cohort before and after receive ChAdOx-1 nCoV-19 or CoronaVac vaccines. Taken together, our results show that the test can be customized at different stages depending on its application, enabling the user to analyze different cohorts, saving time, reagents, or samples. It also represents a valuable tool for elucidating the immunological consequences of new viral strains and for monitoring vaccination coverage and the duration of response to different immunization regimens.

show abstract

Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination

Cited by 17 publications

References 31 publications

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia

On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination

On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination

Contact Info

Product

Resources

About